MRM

MEDIROM Healthcare Technologies Inc. (MRM) SWOT Analysis Analysis (2026)

Invetso Score: 3.1/10 — Weak · Last Updated: 2026-09-01

Strengths

The company’s current ratio of 1.75 supports near-term liquidity, but peers with stronger cash generation typically sustain more flexible working-capital cycles.

A debt-to-equity ratio of 1.75 indicates usable leverage capacity, yet it is less supportive than peers with cleaner balance sheets and lower refinancing sensitivity.

The business can still fund operations through existing liquidity, but its structural resilience trails peers that convert earnings into cash more efficiently.

Weaknesses

Return on invested capital of -19.3% shows capital is destroying value, leaving MRM structurally behind peers that compound returns above their cost of capital.

A cash conversion cycle of 313 days ties up working capital for far longer than peers, which suppresses flexibility and increases funding pressure.

Negative net debt to EBITDA reflects the absence of positive earnings power, so leverage metrics are less informative than peers with stable EBITDA generation.

The combination of weak profitability and slow cash conversion limits reinvestment capacity, making MRM less competitive than peers with stronger operating discipline.

Opportunities

If management shortens the 313-day cash conversion cycle, working-capital release could improve liquidity faster than peers with already efficient cycles.

Any return to positive invested-capital returns would materially narrow the gap versus peers, because the current base is deeply value destructive.

Balance-sheet flexibility could improve if operating performance strengthens, allowing MRM to compete more effectively with peers that already self-fund growth.

Threats

Persistent negative ROIC raises the risk that peers continue to outcompete MRM on reinvestment efficiency, widening the structural performance gap.

The long cash conversion cycle increases exposure to supplier, inventory, and receivables shocks, especially versus peers with faster cash turnover.

If operating losses persist, leverage and liquidity could become more constraining than at peers with stronger earnings coverage and shorter funding cycles.

Overall Score

MRM’s structural positioning is weak versus peers because negative capital returns and an exceptionally long cash conversion cycle outweigh its acceptable near-term liquidity.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on MEDIROM Healthcare Technologies Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →